Evidence map›Paper›PMID 25419481›Full record

ArticleJournal of clinical & cellular immunology2014

An Inflammatory Cytokine Milieu is Prominent in Premalignant Oral Lesions, but Subsides when Lesions Progress to Squamous Cell Carcinoma.

Danielle Woodford, Sara D Johnson, Anna-Maria A De Costa, M Rita I Young

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical & cellular immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Leukoplakia and Immunology: New Chemoprevention Landscapes?International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Danielle WoodfordResearch Service, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA ; Department of Otolaryngology, Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, USA ; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Sara D JohnsonResearch Service, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA ; Department of Otolaryngology, Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, USA.
Anna-Maria A De CostaResearch Service, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA ; Department of Otolaryngology, Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, USA.
M Rita I YoungResearch Service, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA ; Department of Otolaryngology, Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, USA.
MUSC Hollings Cancer Center · US

Funding

Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.R01CA128837 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI YOUNG, M. RITA · 2009 to 2013
$1.5M
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune ReactivityI01CX000100 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI YOUNG, M. RITA · 2009 to 2014
–
Sustaining a Th17 Phenotype to Prevent Premalignant Lesion Progression to CancerI01CX000851 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI YOUNG, M. RITA · 2013 to 2016
–
CSRD VA I01 CX000100CSRD VA I01 CX000851NCI NIH HHS R01 CA128837
6 · The paper itself

Abstract

While head and neck squamous cell carcinomas (HNSCC) are associated with profound immune suppression, less is known about the immunological milieu of premalignant oral lesions. The present study shows dynamic shifts in the immune milieu within premalignant oral lesions and when they have progressed to HNSCC. Specifically, this study showed that the premalignant lesion environment consists of inflammatory mediators and IL-17, but this inflammatory phenotype declines when premalignant oral lesions have progressed to HNSCC. The cytokine profiles of human tissues did not correspond with plasma cytokine profiles. A murine carcinogen-induced premalignant lesion model that progresses to HNSCC was used to examine cytokine profiles released from tissues as well as regional lymph nodes. As in human tissues, murine premalignant lesions and regional lymph nodes released high levels of inflammatory cytokines and, very prominently, IL-17. Also similar to human tissues, release of inflammatory cytokines declined in HNSCC tissues of mice and in the regional lymph nodes of mice with HNSCC. Studies focusing on IL-17 showed that mediators from premalignant lesions stimulated normal spleen cells to produce increased levels of IL-17, while mediators from HNSCC were less stimulatory toward IL-17 production. IL-17 production by Th17-skewed CD4+ cells was strongly inhibited by normal oral epithelium as well as HNSCC. In contrast, premalignant lesion-derived mediators further increased IL-17 production by Th17-skewed cells. The stimulation of IL-17 production by premalignant lesions was dependent on IL-23, which premalignant lesions released in higher amounts than control tissues or HNSCC. HNSCC tissues instead produced increased levels of TGF-β compared to premalignant lesions, and skewed normal spleen cells toward the Treg phenotype. This skewing was blocked by supplementation with IL-23. These studies suggest IL-23 to be a significant contributor to the inflammatory IL-17 phenotype in premalignant oral lesions and suggest the decline in IL-23 in HNSCC leads to a decline in Th17 cells.

Indexed as

CytokinesHNSCCIL-17IL-23InflammationOral cancerPremalignant lesions

Identifiers

PMID25419481
PMCPMC4240319
OpenAlexW2058173364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.